Dossier
David Risinger
Coverage of David Risinger in the Nexus archive.
- STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial
Pfizer's experimental lung cancer drug sigvotatug vedotin failed in a clinical trial, which was expected to replace the chemotherapy docetaxel. The drug was acquired through Pfizer's $43 billion purchase of Seagen in 2023.